Advertisement

Topics

Study to Evaluate the Safety of the Vaccine Prepared sm14 Against Schistosomiasis

2014-08-27 03:12:31 | BioPortfolio

Summary

This is a phase I, open-label, single arm trial, which aims to assess the safety of the vaccine prepared sm14 in healthy subjects. The product immunogenicity will be evaluated by conducting serology (anti-sm14 antibodies) and testing of cellular response to the antigen by the method ELI-SPOT. Each participant will remain in the study for approximately 4 months. The total study duration is 10 months, considering a period of 6 months for inclusion. Will be included in the study subjects male and female, between 18 and 49 years, that manifest their will to participate in the research by signing an Informed Consent Form. Eligible population for the study are subjects who do not present at screening significant changes in renal, cardiac and liver functions, complete blood count, clotting, present no acute or chronic illnesses, are not in the chronic use of any medication, do not have HIV infection or other immunodeficiency. Pregnant or breastfeeding women will not be included. Volunteers will receive three doses of vaccine prepared sm14, in doses containing 50 mcg of the antigen, associated with adjuvant GLA-SE at a dose of 10 mcg, with an interval of 30 days between each application. Twenty volunteers will be included in the study. This is a convenience sample, established for the first test of the product in humans, for the initial safety assessment.

Study Design

Control: Uncontrolled, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention

Conditions

Schistosomiasis

Intervention

sm14 antigen plus adjuvant GLA

Location

Instituto de Pesquisa Clínica Evandro Chagas (IPEC) - Fiocruz
Rio de Janeiro
Brazil
21040900

Status

Not yet recruiting

Source

Oswaldo Cruz Foundation

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:12:31-0400

Clinical Trials [720 Associated Clinical Trials listed on BioPortfolio]

Anti-Schistosomiasis Vaccine: Sm14 Phase 2b-Sn in School Children

The clinical trial phase 2b is designed to assess the safety, the specific immune response and the anti-parasite effect of the active ingredient (protein + adjuvant) in healthy and then in...

Repeated Doses of Praziquantel in Schistosomiasis Treatment (RePST)

An open label, randomized controlled trial of single vs. multiple treatments of praziquantel in intestinal African schistosomiasis in Côte d'Ivoire This study aims to determine the effic...

Schistosomiasis in Senegal

Schistosomiasis is a flatworm transmitted from freshwater snails to humans in the tropics. In addition to this infectious disease, tropical developing countries are faced with malnutrition...

Safety and Immunogencity of H7N9 Influenza Antigen With 2 Adjuvant Formulations in Healthy Adults in Brazil

The overall aim of this study is to evaluate the safety, immunogenicity and dose sparing effects of H7N9 influenza antigen formulated with 2 different adjuvants .

Activity of Mefloquine Against Urinary Schistosomiasis

Urinary schistosomiasis is a debilitating disease in Central Africa and pregnant women are frequently suffering from this condition. Mefloquine is currently investigated as preventive trea...

PubMed Articles [2568 Associated PubMed Articles listed on BioPortfolio]

An immunopotentiator, ophiopogonin D, encapsulated in a nanoemulsion as a robust adjuvant to improve vaccine efficacy.

As an ingredient of vaccines, adjuvants are indispensable for enhancing and directly inducing robust and extensive adaptive immune responses associated with vaccine antigens. In this study, we initial...

History of schistosomiasis (bilharziasis) in humans: from Egyptian medical papyri to molecular biology on mummies.

Schistosomiasis is a parasitic infection that has evolved together with the humankind. Evidence in ancient Egyptian medical papyri or Assyrian medical texts reported signs and symptoms that could rese...

Adjuvant efficacy of G2 (buffalo spleen extraction) against Yersinia septicemia in rainbow trout (Onchorhynchus mykiss).

Adjuvant effect of G2 (extraction of buffalo spleen) was assessed in intraperitoneally immunized rainbow trout (100-150 g) with killed- Y. ruckeri bacterin biotype I [0.1 mL (1 × 10 cells/f...

Measures and achievements of schistosomiasis control in the Yangtze River Basin.

This paper reviewed the prevention and control of schistosomiasis in the Yangtze River Basin in three stages, centered on the measures and achievements. It pointed out the key work of prevention and c...

Experience and insights of schistosomiasis elimination in Yujiang County of Jiangxi Province-Commemoration of the 60th anniversary of publishing Chairman Mao Zedong's two poems"Farewell to the God of Plague".

Schistosomiasis is one of the major infectious diseases that seriously endanger the health of people, and social and economic development. Before the year of 1949, Yujiang County of Jiangxi Province w...

Medical and Biotech [MESH] Definitions

Schistosomiasis caused by Schistosoma japonicum. It is endemic in the Far East and affects the bowel, liver, and spleen,

Schistosomiasis caused by Schistosoma mansoni. It is endemic in Africa, the Middle East, South America, and the Caribbean and affects mainly the bowel, spleen, and liver.

Radiotherapy given to augment some other form of treatment such as surgery or chemotherapy. Adjuvant radiotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.

Drug therapy given to augment or stimulate some other form of treatment such as surgery or radiation therapy. Adjuvant chemotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.

Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity.

More From BioPortfolio on "Study to Evaluate the Safety of the Vaccine Prepared sm14 Against Schistosomiasis"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Vaccines
A vaccine is any preparation intended to produce immunity to a disease by stimulating the production of antibodies. It creates immunity but does not cause the disease. There are several differnt types of vaccine avalable; Killed microorganisms; which s...

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...


Searches Linking to this Trial